Physician profile
Roger J Mcsharry
NPI 1063405736
$2,932.46
in general payments reported to CMS, 2019-2025
23 companies · $191 in 2025
The $191 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $139 · 2021: $172 · 2022: $333 · 2023: $985 · 2024: $794 · 2025: $191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,871 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,870.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,099.41 | 2019-2024 | Tezspire, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $279.15 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.10 | 2020-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $185.75 | 2024-2025 | Dupixent |
| Amgen INC. | $164.89 | 2023-2024 | Tezspire |
| Abiomed | $124.70 | 2022 | |
| Portola Pharmaceuticals, LLC | $113.80 | 2019 | |
| Jazz Pharmaceuticals INC. | $100.00 | 2019 | |
| Grifols USA, LLC | $85.50 | 2022-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $70.27 | 2023-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.58 | 2023 | Glassia |
| Merck Sharp & Dohme LLC | $58.31 | 2024 | Zerbaxa, Keytruda |
| Baxter Healthcare | $53.31 | 2023-2024 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $46.11 | 2022-2024 | Acthar |
| Pfizer INC. | $45.59 | 2023-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $45.38 | 2022-2024 | Tyvaso |
| Genzyme Corporation | $44.14 | 2022-2024 | |
| Sunovion Pharmaceuticals INC. | $32.79 | 2019-2021 | |
| Daiichi Sankyo INC. | $26.89 | 2023 | Injectafer |
| Ani Pharmaceuticals, INC. | $26.05 | 2023 | Purified Cortrophin Gel |
| Shionogi INC | $25.78 | 2024 | Fetroja |
| Advanced Respiratory, INC | $21.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.41 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Mcsharry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.